BIIB Stock Price Today (October 2026) — Biogen Inc. Analysis & Key Metrics 2026-10-20
Biogen Inc. (BIIB) is trading at $243.10, up 4.12% today (as of October 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $243.98 (0.4% upside).
- Volatility is low (23.61% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: steady revenue (3.40% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
BIIB Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Biogen Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $42.99B
P/E Ratio
Forward P/E: 13.10
Revenue Growth
Year over Year
Analyst Target
+0.4% upside potential
Key Investor Questions About BIIB
What investors need to know before buying
Based on current market data, BIIB presents a overbought technical setup with mixed signals fundamentals.
- Technicals say: Overbought (RSI 75.23)
- Fundamentals say: Mixed signals (nuanced financial profile)
BIIB's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for BIIB investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $8.36B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, BIIB stock traded between $138.00 and $240.99 and currently trades near the high end of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.61% annualized volatility and β=0.47, the stock exhibits low sensitivity to market moves—making BIIB suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
RBC Capital names top healthcare stocks as sector upgraded to overweight
Wells Fargo Adjusts Price Target on Biogen to $310 From $250
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
Wedbush Trims Price Target on Biogen to $212 From $215, Keeps Neutral Rating
Latest TickZen Insights
All insights →No TickZen article on BIIB yet. Our newest analysis:
Explore More Analysis for BIIB
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 28, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Biogen Inc.
Biogen Inc. (BIIB) is currently trading at $243.10. The RSI (14-day) is at 75.2, indicating overbought territory (potentially overheated). Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $243.98 implies 0.4% upside from current levels. Volatility is moderate at 23.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Biogen Inc. (BIIB): The trailing P/E ratio is 38.88, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 13.10, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.56, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 1.70. Price-to-Sales is 3.20. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 32 analysts covering BIIB, the consensus price target is $243.98. This represents a 0.4% upside from the current price of $243.10. The range spans from a low target of $175.00 to a high target of $300.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Biogen Inc. (BIIB) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Biogen Inc. (BIIB) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Biogen Inc.'s (BIIB) current debt and financial health profile: Total debt stands at $8.36B. The debt-to-equity ratio is 0.44x, which is moderate and generally manageable for most companies. The current ratio is 1.87, indicating strong short-term liquidity. The quick ratio is 0.94. The company holds $1.28B in cash and equivalents. Free cash flow is positive at $1.27B, providing a cushion for debt servicing and shareholder returns.